Correlation Between AN2 Therapeutics and Oncorus
Can any of the company-specific risk be diversified away by investing in both AN2 Therapeutics and Oncorus at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AN2 Therapeutics and Oncorus into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between AN2 Therapeutics and Oncorus, you can compare the effects of market volatilities on AN2 Therapeutics and Oncorus and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AN2 Therapeutics with a short position of Oncorus. Check out your portfolio center. Please also check ongoing floating volatility patterns of AN2 Therapeutics and Oncorus.
Diversification Opportunities for AN2 Therapeutics and Oncorus
-0.84 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between AN2 and Oncorus is -0.84. Overlapping area represents the amount of risk that can be diversified away by holding AN2 Therapeutics and Oncorus in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncorus and AN2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AN2 Therapeutics are associated (or correlated) with Oncorus. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncorus has no effect on the direction of AN2 Therapeutics i.e., AN2 Therapeutics and Oncorus go up and down completely randomly.
Pair Corralation between AN2 Therapeutics and Oncorus
If you would invest 108.00 in AN2 Therapeutics on September 22, 2024 and sell it today you would earn a total of 18.00 from holding AN2 Therapeutics or generate 16.67% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Significant |
Accuracy | 2.33% |
Values | Daily Returns |
AN2 Therapeutics vs. Oncorus
Performance |
Timeline |
AN2 Therapeutics |
Oncorus |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
AN2 Therapeutics and Oncorus Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with AN2 Therapeutics and Oncorus
The main advantage of trading using opposite AN2 Therapeutics and Oncorus positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AN2 Therapeutics position performs unexpectedly, Oncorus can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncorus will offset losses from the drop in Oncorus' long position.AN2 Therapeutics vs. Aerovate Therapeutics | AN2 Therapeutics vs. Adagene | AN2 Therapeutics vs. Acrivon Therapeutics, Common | AN2 Therapeutics vs. Rezolute |
Oncorus vs. Apollomics Class A | Oncorus vs. Pyxis Oncology | Oncorus vs. Zura Bio Limited | Oncorus vs. Altamira Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data |